
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics Inc is making significant strides in addressing healthcare costs associated with challenging cancer treatments, particularly through its CNSide product, which may reduce leptomeningeal metastases-related costs by approximately 40%. The receipt of an $18 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to study leptomeningeal metastases further supports the company's strategic development and resource allocation. Additionally, positive FDA Type B feedback regarding accelerated approval for key drug candidates enhances market confidence in Plus Therapeutics’ potential for successful commercialization and reimbursement outcomes.
Bears say
The financial analysis indicates concerns regarding Plus Therapeutics's stock, primarily driven by its planned 1-for-25 reverse stock split, which typically reflects underlying capital market difficulties in small-cap biotechnology companies and may impact trading liquidity. Furthermore, the company reported an operating loss of $15.3 million and a net loss of $22.4 million for the full year 2025, even as it ended the year with $13.1 million in cash and investments, highlighting significant financial strains. Lastly, potential risks such as failure to achieve clinical trial success, secure regulatory approvals, and navigate competitive pressures further contribute to a negative outlook for the company's future financial stability and growth.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares